Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 2

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell, Cutaneous 4Leukemia-Lymphoma, Adult T-Cell 4Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3Carcinoma 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

zanolimumab 3mogamulizumab 3denileukin diftitox 2Vorinostat 2Vitamin B 12 2Panobinostat 2Folic Acid 210-propargyl-10-deazaaminopterin 2resminostat 1ontuxizumab 1navitoclax 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Bexarotene 1A-dmDT390-bisFv(UCHT1) protein 1(N(1),N(12))bis(ethyl)-6,7-dehydrospermine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Sezary Syndrome × mogamulizumab × Clear all
NCT07132567 2025-09-22

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Kyowa Kirin Co., Ltd.

Recruiting
15 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT05455931 2024-09-04

PROSPER

Kyowa Kirin Co., Ltd.

Active not recruiting
73 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Kyowa Kirin Co., Ltd.

Phase 3 Completed
372 enrolled 14 charts 1 FDA
DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡